Please assess the completion status of the following clinical trial:

Trial Title: CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed B-cell non-Hodgkin's lymphoma, including the following subtypes:~  * Aggressive B-cell lymphoma (Group A)~    * Diffuse large B-cell lymphoma~   * Transformed lymphoma~ * Follicular lymphoma (Group B)~ * Small lymphocytic lymphoma~    * Chronic lymphocytic leukemia (CLL) (Group C)~   * Other B-cell small lymphocytic disorders~* No mantle cell lymphoma~* No potentially curative treatment options because of lack of response, relapse, or ineligibility~* Relapsed or refractory disease~* Patients with refractory disease (i.e., less than a partial response to the last treatment) must have received no more than 3 prior regimens (group A)~* Patients with sensitive disease (i.e., at least a partial response to the last treatment) must have received no more than 4 prior regimens (group A)~* Patients who have failed prior autologous transplantation are eligible (group A)~  * No more than 5 prior regimens (groups B and C)~ * The salvage regimen, conditioning regimen, and any maintenance therapy are considered 1 regimen~* Prior rituximab or alemtuzumab is not considered prior therapy~* No limitation to the amount of prior radiotherapy~* No CNS involvement~* Performance status: ECOG 0-2 OR Karnofsky 60-100%~* Life expectancy more than 3 months~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~* No prior allergic reactions attributed to compounds of similar chemical or biological composition to CCI-779~* No ongoing or active infection~* No psychiatric illness or social situation that would preclude study compliance~* No other active malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix Completed therapy and considered \< 30% risk of relapse~* No other concurrent uncontrolled illness~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No concurrent prophylactic hematopoietic colony-stimulating factors~* No concurrent pegfilgrastim~* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered~* More than 4 weeks since prior radiotherapy and recovered~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No concurrent unconventional therapies, food, or vitamin supplements containing Hypericum perforatum (St. John's wort)~* No other concurrent known inducers of CYP3A4~* No other concurrent investigational agents~* No other concurrent anticancer therapy~* Measurable disease\*~  * At least 1 unidimensionally measurable lesion \>= 20 mm by conventional techniques OR \>= 10 mm by spiral CT scan \[Note: \*Only bone marrow or peripheral blood involvement required for CLL and Waldenstrom's macroglobulinemia \]~* Absolute neutrophil count \>= 1,000/mm3~* Bilirubin =\< 1.5 times upper limit of normal (ULN)~* AST and ALT =\< 2.5 times ULN~* Creatinine =\< 1.5 times ULN~* Fasting cholesterol =\< 350 mg/dL~* Fasting triglycerides =\< 400 mg/dL~* Platelet count \>= 50, 000/mm3 (\> 20,000/mm3 for patients with thrombocytopenia due to bone marrow involvement)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).